White House to Unveil Partnership with Regeneron Pharmaceuticals
The White House is set to announce a new partnership with Regeneron Pharmaceuticals, aiming to transform drug pricing in the United States. This initiative comes after a year-long campaign targeting over a dozen pharmaceutical companies, urging them to provide discounted prices in exchange for tariff relief. Regeneron, the last remaining company to finalize a deal, has agreed to lower Medicaid prices for its existing and upcoming drugs.
Details of the Agreement
Under the new agreement, Regeneron will sell its cholesterol-lowering medication, Praluent, at a price of $225. This information was confirmed by a White House official. This medication will feature on President Donald Trump’s drug pricing portal, TrumpRx, which aims to connect Americans with discounted medications.
New Drug Approval and Accessibility
- Regeneron will soon announce the approval of its latest drug, Otarmeni, a gene therapy for children suffering from a rare type of hearing loss.
- The company plans to provide Otarmeni free of charge to those in need.
The announcement event, scheduled for Thursday afternoon, will highlight a compelling story of a mother whose child successfully regained hearing through the use of Otarmeni. This personal touch underscores the significance of the new partnership.
Impact on Drug Pricing
Drug pricing has been a focal point of Donald Trump’s domestic policy. Last summer, he called on 17 major pharmaceutical companies to align their prices with the lowest rates paid by other developed nations, a strategy termed “Most Favored Nation.” Regeneron stands out among these companies as it was the last to strike a deal.
Domestic Manufacturing Commitment
Regeneron has pledged nearly $10 billion towards enhancing its domestic manufacturing capabilities, which is expected to bolster production within the United States.
Criticism and Broader Context
Despite the administration’s enthusiasm, experts caution that these agreements may have limited effects. Critics note that Medicaid already pays lower prices compared to Medicare and private insurers, which are not included in these deals. Furthermore, many drugs on TrumpRx were available at lower prices prior to these negotiations.
Since these agreements were announced, several pharmaceutical companies, including Regeneron, have committed to providing drugs for free to individuals in need. Conversely, there are concerns, as some companies have increased prices at the beginning of the year, despite being part of the agreement.
Legislative Efforts and Future Steps
The White House has proposed legislation that would mandate drugmakers to utilize “Most Favored Nation” pricing within government insurance programs. This move has raised questions during recent congressional hearings, where Health Secretary Robert F. Kennedy Jr. faced pressure to disclose the terms of these pharmaceutical deals, but he refrained from sharing specifics, referring to them as “proprietary information.”
Regeneron’s Successful Products
- Regeneron’s flagship product is Dupixent, used for severe eczema and autoimmune disorders.
- The company also markets Eylea, a remedy for macular degeneration, and Kevzara, used in rheumatoid arthritis treatment.
This new partnership between the White House and Regeneron Pharmaceuticals signals a significant step in the ongoing efforts to tackle high drug prices in the United States. As these developments unfold, the administration’s impact on the pharmaceutical industry will be closely monitored by both supporters and critics.
